OMARIGLIPTIN

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C17H20F2N4O3S
Molecular Weight	398.428
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4

InChI

InChIKey=MKMPWKUAHLTIBJ-ISTRZQFTSA-N

InChI=1S/C17H20F2N4O3S/c1-27(24,25)23-7-10-6-22(8-16(10)21-23)12-5-15(20)17(26-9-12)13-4-11(18)2-3-14(13)19/h2-4,7,12,15,17H,5-6,8-9,20H2,1H3/t12-,15+,17-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C17H20F2N4O3S
Molecular Weight	398.428
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=36234 | https://www.ncbi.nlm.nih.gov/pubmed/27372109 | https://www.ncbi.nlm.nih.gov/pubmed/26507988

Omarigliptin is a new once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor developed for the treatment of type 2 diabetes. It potently but reversibly inhibits DPP-4 enzyme, which prolongs the circulating half-life of glucagon-like peptide-1 that increases insulin secretion in a glucose-dependent manner. Benefiting from glucose-dependent insulin secretion, omarigliptin is associated with low risk of hypoglycemia. Marizev (omarigliptin) 25 mg and 12.5 mg tablets were approved by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) on 28th Sept 2015. Japan was the first country to have approved omarigliptin.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dipeptidyl peptidase IV 37 Target ID: CHEMBL284 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27396490 \| https://www.ncbi.nlm.nih.gov/pubmed/24660890	Inhibitor 8504		2.22 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 262 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=36234 https://clinicaltrials.gov/ct2/show/NCT01697592 http://adisinsight.springer.com/drugs/800031846	Primary		Approved 8583	Marizev Approved Use Marizev is used to treat type 2 diabetes. Launch Date 2015

C_max

Value	Dose	Analyte	Population
549 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=26 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=37	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
523 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=26 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=37	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
141.51 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
749.54 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2709.59 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
297.84 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1712.32 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
223.03 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
15.66 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	1 mg 1 times / week multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
21.25 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	1 mg 1 times / week multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
236.65 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	10 mg 1 times / week multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
278.21 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	10 mg 1 times / week multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
802.6 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	25 mg 1 times / week multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
700.63 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	25 mg 1 times / week multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1083.59 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	50 mg 1 times / week multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1305.97 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	50 mg 1 times / week multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.45 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
20.7 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	1.5 mg single, oral dose: 1.5 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
88.2 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
219 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	12.5 mg single, oral dose: 12.5 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
484 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
904 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2210 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3850 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9290 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
206 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=70	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
195 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=70	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
184 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	10 mg 1 times / week multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
195 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	10 mg 1 times / week multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
610 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	25 mg 1 times / week multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
565 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	25 mg 1 times / week multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
988 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	50 mg 1 times / week multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1080 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	50 mg 1 times / week multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2320 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	100 mg 1 times / week multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2400 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	100 mg 1 times / week multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
60.4 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
61.4 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
48.7 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
41.4 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
41 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
56.1 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
572 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=38 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=125	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
554 nM OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=38 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=125	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
22.7 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=26 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=37	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
23 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=26 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=37	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
5.34 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
23.81 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
94.63 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.07 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
48.66 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.75 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
1.03 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	1 mg 1 times / week multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.4 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	1 mg 1 times / week multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.92 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	10 mg 1 times / week multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.75 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	10 mg 1 times / week multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
21.19 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	25 mg 1 times / week multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
22.31 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	25 mg 1 times / week multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
40.32 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	50 mg 1 times / week multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
41.56 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	50 mg 1 times / week multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.147 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.2 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	1.5 mg single, oral dose: 1.5 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.13 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10.6 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	12.5 mg single, oral dose: 12.5 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
20.9 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
39.4 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
82.5 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
155 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
323 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.59 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=70	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.99 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=70	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
7.37 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	10 mg 1 times / week multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.76 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	10 mg 1 times / week multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
22 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	25 mg 1 times / week multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
22 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	25 mg 1 times / week multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
40.7 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	50 mg 1 times / week multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
47.8 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	50 mg 1 times / week multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
82.3 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	100 mg 1 times / week multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
87.8 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	100 mg 1 times / week multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3055 nM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3675 nM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3580 nM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3352 nM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3151 nM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2432 nM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
22.4 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=38 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=125	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
23.8 μM × h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=38 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=125	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
46.8 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=26 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=37	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
46 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=26 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=37	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
66.65 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
38.89 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
43.41 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
49.91 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
33.43 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
89.45 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
144.88 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	1 mg 1 times / week multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
143.52 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	10 mg 1 times / week multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
82.48 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	25 mg 1 times / week multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
73.73 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	50 mg 1 times / week multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
93.3 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	1.5 mg single, oral dose: 1.5 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
115.94 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
68.88 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	12.5 mg single, oral dose: 12.5 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
49.52 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
47.65 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
42.62 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
45.19 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
42.45 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
119.59 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=70	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
98.22 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=70	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
83.18 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	10 mg 1 times / week multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
66.74 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	25 mg 1 times / week multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
48.3 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	50 mg 1 times / week multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
41.74 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	100 mg 1 times / week multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
148 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
156 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
160 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
215 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
264 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
163 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
34.6 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=38 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=125	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
34.5 h OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=38 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=125	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	OMARIGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
24% OTHER GOV'T https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=27 \| https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_I100_1.pdf#page=21			OMARIGLIPTIN plasma	Homo sapiens

Doses

Dose	Population	Adverse events
100 mg 1 times / week multiple, oral Highest studied dose Dose: 100 mg, 1 times / week Route: oral Route: multiple Dose: 100 mg, 1 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA	Other AEs: Headache, Dizziness... Other AEs: Headache Dizziness Dizziness postural Head discomfort Nausea Diarrhea Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA
400 mg single, oral Highest studied dose Dose: 400 mg Route: oral Route: single Dose: 400 mg Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA	Other AEs: Headache, Dry mouth... Other AEs: Headache Dry mouth Nausea Migraine Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA

AEs

AE	Dose	Population
Diarrhea	100 mg 1 times / week multiple, oral Highest studied dose Dose: 100 mg, 1 times / week Route: oral Route: multiple Dose: 100 mg, 1 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA
Dizziness postural	100 mg 1 times / week multiple, oral Highest studied dose Dose: 100 mg, 1 times / week Route: oral Route: multiple Dose: 100 mg, 1 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA
Dizziness	100 mg 1 times / week multiple, oral Highest studied dose Dose: 100 mg, 1 times / week Route: oral Route: multiple Dose: 100 mg, 1 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA
Head discomfort	100 mg 1 times / week multiple, oral Highest studied dose Dose: 100 mg, 1 times / week Route: oral Route: multiple Dose: 100 mg, 1 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA
Headache	100 mg 1 times / week multiple, oral Highest studied dose Dose: 100 mg, 1 times / week Route: oral Route: multiple Dose: 100 mg, 1 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA
Nausea	100 mg 1 times / week multiple, oral Highest studied dose Dose: 100 mg, 1 times / week Route: oral Route: multiple Dose: 100 mg, 1 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA
Dry mouth	400 mg single, oral Highest studied dose Dose: 400 mg Route: oral Route: single Dose: 400 mg Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA
Headache	400 mg single, oral Highest studied dose Dose: 400 mg Route: oral Route: single Dose: 400 mg Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA
Migraine	400 mg single, oral Highest studied dose Dose: 400 mg Route: oral Route: single Dose: 400 mg Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA
Nausea	400 mg single, oral Highest studied dose Dose: 400 mg Route: oral Route: single Dose: 400 mg Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/27225334/ https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA

PubMed

Title	Date	PubMed
Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.	2014-04-24	24660890

Patents

Sample Use Guides

In Vivo Use Guide

For adults, take 2 tablets (25 mg of the active ingredient) at a time, once a week. If you are a patient with severe or end stage renal dysfunction, take 1 tablet (12.5 mg) at a time, once a week.

Route of Administration: Oral

In Vitro Use Guide

Omarigliptin is a competitive, reversible inhibitor of DPP-4 (IC50 = 1.6 nM, Ki = 0.8 nM) and is more potent than sitagliptin (IC50 = 18 nM). It is highly selective over all proteases tested (IC50 > 67 uM), including QPP, FAP, PEP, DPP8, and DPP9. The compound has weak ion channel activity (IC50 > 30 uM at IKr, Cav1.2, and Nav1.5). An expansive selectivity counterscreen (168 radioligand binding or enzymatic assays) was carried out at MDS Pharma. An IC50 > 10 uM was obtained in all assays.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 20:57:22 GMT 2025` Edited by `admin` on `Mon Mar 31 20:57:22 GMT 2025`
Record UNII	CVP59Q4JE1
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MK-3102

Preferred Name

English

OMARIGLIPTIN

Official Name

English

OMARIGLIPTIN [USAN]

Common Name

English

omarigliptin [INN]

Common Name

English

OMARIGLIPTIN [MI]

Common Name

English

2H-PYRAN-3-AMINE, 2-(2,5-DIFLUOROPHENYL)-5-(2,6-DIHYDRO-2-(METHYLSULFONYL)PYRROLO(3,4-C)PYRAZOL-5(4H)-YL)TETRAHYDRO-,(2R,3S,5R)-

Common Name

English

OMARIGLIPTIN [JAN]

Common Name

English

Omarigliptin [WHO-DD]

Common Name

English

Code System Code Type Description

USAN

YY-120